Commercialization: Page 74
-
PharmaVoice Team/PharmaVoice
Practical Medicine:
Diagnosing the condition DERMAN. Insurance and reimbursement are two big challenges. Part of the problem is that reimbursement rates have dropped, thus physicians need to see more patients, more efficiently, in the same period of time to cover overhead. This is true even in an academic environmen...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Xyrem: Awakenings
PharmaVOICE approved for treating cataplexy. Of the esti mated 140,000 Americans who suffer from narcolepsy, between 60% and 90% experience cataplexy. Orphan Medical Inc. developed Xyrem under the FDA’s Orphan Drug Act of 1983, which provides market exclusivity to companies that develop products ...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Brand-cycle management
By 2005, many multibillion dollar drugs will come off patent, including blockbuster drugs such as Claritin, Viagra, Glucophage, and Prilosec (see chart on page 51). The finan cial incentives for prolonging the life of these brands are enormous. Last year, Claritin earned almost $2 billion in sale...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Dr. Jack GOLDSTEIN Chiron Names Blood Testing Division President Chiron Corp. has named Jack Goldstein, Ph.D., president of Chi ron’s blood testing division. Dr. Goldstein is responsible for the commercial operations of Chiron’s blood testing business, based in Emeryville, Calif. He a...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES The Rosetta Luminator system, a clientserver bioinformatics system for storing and analyzing microarray data, has been launched by Rosetta Biosoftware and Agilent Technologies Inc. The geneexpression data analysis solution was deve...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES TrialCard’s patented “IA Technology” is designed to replace prepackaged drug samples. By using a device similar to a credit card that can be activated and deactivated, manufacturers can distribute their samples through pharmacies, and can im...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
NEUROTHERAPEUTICS AND GENE AMPLIFICATION Markets Predicted to Grow Unmet need and ballooning incidence are expected to create huge market potential in neuro logical drugs,according to a study by Kalorama Infor mation. The world market stands at $70 billion, but steady growth in demand and product...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
For Art's Sake
CREATIVE review There are many times in healthcare advertising when humor is not appropriate,but for every ad that misuses humor there are hundreds of others that have wasted the opportunity to elicit a chuckle or to add a touch of irony. Humor is one of the most underutilized tools that we have....
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
Fewer new drug approvals, the political spotlight on the pharmaceutical industry, promotional budget cutbacks. What else can go wrong in the healthcare communications industry? Pitted against their more endowed competitors, small agencies may be wellsuited to survive in today’s adverse environmen...
By Rico Viray • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
Raise Your Voice: Letters
Missed opportunity I applaud the fact that PharmaVOICE has highlighted the importance of the new PhRMA Voluntary Marketing Code, but I would be remiss if I didn’t ask: “Where in this article is the discussion about the benefit of the new code to the patient?” In reading through this 11 page artic...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Virginia Kirk Denise Myshko Elisabeth Pena Kim Ribbink Alex Robinson Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, Numb...
By Taren Grom • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
The Value of Innovation
BY ALEX ROBINSON Let’s stop complaining about spending on prescription drugs,” Alan Holmer, president of the Phar maceutical Research and Manufacturers of Ameri ca (PhRMA) told an audience in April. “In fact, let’s hope that prescription drug spending goes up — not down.” Critics are quick to poi...
By Alex Robinson • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Margaret M.FORAN Chuck HARDWICK Pat KELLY Ian READ Pfizer Names Presidents for U.S., European Pharmaceuticals Businesses,Head of Corporate Affairs, and Corporate Secretary Pat Kelly and Ian Read have been appointed presidents responsible for the U.S. and European pharmaceuticals busin...
By PharmaVoice Team • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEB BASED APPLICATIONS, SITES, AND TECHNOLOGIES MDchoice.com Inc. has unveiled a new marketing platform that allows hospitals, clinics, and physician groups to offer their own private label online healthcare information services. The platform offers health information ranging f...
By PharmaVoice Team • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARE RELATED PRODUCTS, SERVICES, AND COMPANIES Dorland Sweeney Jones Health Communications is reaffirming its position as a leader in global health communications and creating a power brand by simplifying its name and organizational structure. The agency has returned to its original nam...
By PharmaVoice Team • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Teams and effective practices that drive corporate growth. “Successful new product plan ning efforts realize that analytical teamstaffing efforts are essential to today’s blockbuster products,” says Paul Meade, VP at Best Prac tices. “Teams that have well rounded members who can bring a combinati...
By PharmaVoice Team • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
Incentive Compensation
As the new environment of pharma sales shifts to more specialized and consumer-centric approaches, the industry will need to respond to adequately compensate and incentivize its sales teams. Our experts say prescription numbers will remain the predominant measurement for sales rep performance in...
By Robin Robinson • Dec. 29, 2009 -
PharmaVoice Team/PharmaVoice
Contents
In Every Issue 3 Letter from the Editor 8 Upfront A brief review of industry news at press time 36 Pharma Trax Sales, marketing, and R&D trends from industry analysts 40 What’s New New healthcare-related products, services, and companies 42 E-Media New electronic and Web-based applications, s...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Pharmaceutical Manufacturing Under Scrutiny
Across the board — from labeling and marketing, to clinical trials, to manufacturing processes — regulators are becoming more active in safeguarding the public and ensuring the safety of pharmaceuticals. Even before the news broke regarding Genzyme Corp.’s recent virus and contamination problems ...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Name That Brand: A Pilot Program
The eventual outcome of the FDA’s two-year Proprietary Name Review pilot project may have positive implications for the industry in the long run, but in the short term, it means more money spent and more time pressure for marketers. Our experts say the burden on pharma companies to conduct their ...
By Robin Robinson • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Last Word
taking stock of the media After the two-day hearing, do you believe FDA officials have a better understanding of social media and what the industry is trying to achieve? Gratton: I think we are at the beginning of the process. Does the FDA understand all of the nuances of the digital landscape —...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Diane JORKASKY Aileron Therapeutics Appoints Medical Chief Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled peptides, has appointed Diane Jorkasky, M.D., senior VP, head of development and chief medical of...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
What's New
Oncology Performance Edge, Health Strategies Group’s recently launched strategic research service, helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources. “The oncology market is significantly different from others,...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Most Americans Want More Info on New Biotechnologies Sidebars: What Do You Think Synthetic Biology Is? Rating the Best Drivers of Attendance to speaker events Pharma Rebranding of Speaker Events Is Paying Off Japan Prese...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
UpFront
Honors and Awards GCPj Bestows Honors The Global Clinical Practices Journal (GCPj) recognized several companies in 2009 for providing excellence in the clinical trials industry: • Chiltern’s Katie Huffine, BSN, MSN, won Project Manager of the Year. • Cognizant and AstraZeneca won the Clinical ...
By PharmaVoice Team • Dec. 28, 2009
Previous
